Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8759336 | 1.00 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL31487414 | 1.00 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL17711236 | 1.00 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL10650846 | 0.96 | MEN1 (0.44) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL29421098 | 0.96 | MEN1 (0.44) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL29496543 | 0.96 | MEN1 (0.44) | MEN1KMT2APRCPDPP7CTSC | |
| Trifluoroacetic Acid SCHEMBL29808681 | 0.94 | MEN1 (0.43) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL30973948 | 0.93 | MEN1 (0.42) | MEN1KMT2APRCPDPP7MAPK8 | |
| SCHEMBL29721158 | 0.92 | MAPK8 (0.43) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL30712166 | 0.92 | MAPK8 (0.43) | MEN1KMT2APRCPDPP7CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103700-A1 | REGULATION OF RAN TRANSLATION BY PKR AND EIF2A-P PATHWAYS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-04-16 | — | — | US | claimed |
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | L'OREAL (FR) | 2026-03-05 | — | — | US | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250375466-A1 | MANIPULATION OF EIF3 TO MODULATE REPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-12-11 | — | — | US | claimed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-12364707-B2 | Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-07-22 | — | — | US | claimed |
| WO-2025092703-A1 | PHOTOSENSITIZER CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 同宜医药（苏州）有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119909192-A | Photosensitizer conjugate compound, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | claimed |
| CN-119614675-A | Wetting liquid formula for improving sample preservation effect | 上海健采医疗器械有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-0565863-B1 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0565862-B1 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0618234-B1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN SPA (IT) | 1997-06-04 | — | — | EP | claimed |
| US-5430133-A | Semi-synthetic glycosaminoglycans with heparin or heparan structure of α-L-iduronic-2-O-sulfate acid modified in position 2 | ALFA WASSERMANN S.P.A. (IT) | 1995-07-04 | — | — | US | claimed |
| US-5410039-A | Process for the synthesis of glycosaminoglycans containing α-L-galacturonic acid substituted with nucleophilic groups in position 3 | ALFA WASSERMANN S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-5405949-A | Process for the synthesis of glycosaminoglycans with heparin or heparan structure modified in position 2 of the α-L-iduronic-2-O-sulfate acid | ALFA WASSERNANN S.P.A. (IT) | 1995-04-11 | — | — | US | claimed |
| EP-0618235-A1 | Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0618234-A1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | MEN1 2259/4885KMT2A 2460/4885PRCP 73/4885 |
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | TYR, CUTA, ARGLU1 | MEN1 2073/4885KMT2A 4225/4885PRCP 4092/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | MEN1 1576/4885KMT2A 2977/4885PRCP 553/4885 |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | ARGLU1, ARG1, FCGRT | MEN1 2259/4885KMT2A 2460/4885PRCP 73/4885 |
| US-20260103700-A1 | REGULATION OF RAN TRANSLATION BY PKR AND EIF2A-P PATHWAYS | EIF2A, EIF2AK1, EIF2AK3 | MEN1 4735/4885KMT2A 1730/4885PRCP 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.